---

UNITED STATES

**FORM
10-QSB**

[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For Quarter Ended**September 30, 2004**

[   ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from     to

Commission File No. 33-55254-28

**INNOVATE ONCOLOGY, INC.**(formerly known as Hampton Berkshire Insurance & Financial
Company)
(Exact name of registrant as specified in its charter)



712 Fifth Avenue, 19th Floor New York, NY 10019

Registrant's telephone number including area code:		(646) 723-8944



Yes X	No



---

**PART 1.  FINANCIAL INFORMATION**

**ITEM 1 - FINANCIAL STATEMENTS**

The condensed financial statements included herein have been prepared by the Company,
pursuant to the rules and regulations of the Securities and Exchange Commission.

In the opinion of the Company, all adjustments, consisting of only normal recurring
adjustments, necessary to present fairly the financial position of the Company as of September 30,
2004 and the results of its operations and changes in its financial position from December 31, 2003
through September 30, 2004 have been made.  The results of its operations for such interim period
is not necessarily indicative of the results to be expected for the entire year.

---



INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial Company)

BALANCE SHEETS

|                                                  | (Unaudited)           |  |                      
|------------------------------------------------- | --------------------- |  | ---------------------
|                                                  | September 30,         |  | December 31,         
|                                                  | 2004                  |  | 2003                 
|                                                  |                       |  |                      
|ASSETS                                            | $                   - |  | $                   -
|                                                  |                       |  |                      
|LIABILITIES & STOCKHOLDER'S EQUITY                |                       |  |                      
|Current Liabilities                               |                       |  |                      
|Accounts Payable                                  | $	10,380              |  | $	3,637              
|Accrued Interest                                  | 3,209                 |  | 1,166                
|Notes Payable                                     | 25,140                |  | 25,140               
|Total Current Liabilities                         | 38,729                |  | 29,943               
|                                                  |                       |  |                      
|Stockholders' Equity                              |                       |  |                      
|Preferred Stock, $.001 par value;                 |                       |  |                      
|25,000,000 shares authorized; None issued         | -                     |  | -                    
|Common Stock, $.001 par value: 125,000,000 shares |                       |  |                      
|authorized, issued and outstanding 6,479,832 at   |                       |  |                      
|September 30, 2004 and December 31, 2003          | 6,480                 |  | 6,480                
|Additional Paid-in Capital                        | 4,794,121             |  | 4,794,121            
|Accumulated Deficit                               | (4,839,330)           |  | (4,830,544)          
|Total Stockholders' Equity                        | (38,729)              |  | (29,943)             
|                                                  |                       |  |                      
|TOTAL LIABILITIES &  STOCKHOLDERS' EQUITY         | $                   - |  | $                   -
|                                                  |                       |  |                      





The accompanying notes are an integral part of these financial statements.

---

INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial, Company)

STATEMENTS OF OPERATIONS

(UNAUDITED)

|                                  | For the Three Months |  | For the Nine Months
|--------------------------------- | -------------------- |  | -------------------
|                                  | Ended                |  | Ended              
|                                  | September 30,        |  | September 30,      
|                                  | 2004                 |  | 2003               
|                                  |                      |  |                    
|REVENUES                          | $               -    |  | $                - 
|                                  |                      |  |                    
|OPERATING EXPENSES                |                      |  |                    
|General & Administrative          | 1,451                |  | 2,665              
|Gain on Settlement of Liabilities | -                    |  | -                  
|Total Operating Expense           | (1,451)              |  | (2,665)            
|                                  |                      |  |                    
|OTHER INCOME (EXPENSE)            |                      |  |                    
|Interest Expense                  | (681)                |  | (47,159)           
|Total Other Income (Expense)      | (681)                |  | (47,159)           
|                                  |                      |  |                    
|NET LOSS                          | $	(2,132)            |  | $	(49,824)         
|                                  |                      |  |                    
|NET LOSS PER COMMON SHARE         | $               -    |  | $	(0.01)           
|                                  |                      |  |                    
|WEIGHTED AVERAGE NUMBER OF        |                      |  |                    
|OUTSTANDING (BASIC & DILUTED)     | 6,479,832            |  | 5,111,882          
|                                  |                      |  |                    



The accompanying notes are an integral part of these financial statements.

---



INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial, Inc.)

STATEMENTS OF CASH FLOWS

(UNAUDITED)

|                                                      |  | For the Nine Months Ended
|----------------------------------------------------- |  | -------------------------
|                                                      |  | September 30,            
|                                                      |  | 2004                     
|CASH FLOWS FROM OPERATING ACTIVITIES:                 |  |                          
|Net Loss                                              |  | $	(8,786
)               
|Adjustments to reconcile net loss to net cash used in |  |                          
|operating activities:                                 |  |                          
|Expense related to issuance of common stock           |  |                          
|and common stock options for services                 |  | -                        

|Changes in Assets and Liabilities:        |  |                       |  |                      
|----------------------------------------- |  | --------------------- |  | ---------------------
|Increase (Decrease) Accounts Payable      |  | 6,743                 |  | (8,923)              
|Increase (Decrease) Interest Payable      |  | 2,043                 |  | 174,137              
|                                          |  |                       |  |                      
|Net Cash Used in Operating Activities     |  | -                     |  | (19,340)             
|                                          |  |                       |  |                      
|CASH FLOWS FROM INVESTING ACTIVITIES:     |  |                       |  |                      
|Net Cash Used in Investing Activities     |  | -                     |  | -                    
|                                          |  |                       |  |                      
|CASH FLOWS FROM FINANCING ACTIVITIES:     |  |                       |  |                      
|Proceeds from Notes payable               |  | -                     |  | 19,340               
|Proceeds from Issuance of Common Stock    |  | -                     |  | -                    
|Net Cash Provided by Financing Activities |  | -                     |  | 19,340               
|                                          |  |                       |  |                      
|NET INCREASE IN CASH                      |  | -                     |  | -                    
|CASH AT BEGINNING OF THE YEAR             |  | -                     |  | -                    
|CASH AT END OF THE YEAR                   |  | $                   - |  | $                  - 
|                                          |  |                       |  |                      
|SUPPLEMENTAL DISCLOSURE OF CASH FLOW      |  |                       |  |                      
|Cash paid during the year for interest    |  | $                   - |  | $                   -
|                                          |  |                       |  |                      

---

SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING & FINANCING ACTIVITIES:

None.

The accompanying notes are an integral part of these financial statements.

---

INNOVATE ONCOLOGY, INC.(Formerly known as Hampton Berkshire Insurance & Financial Company)NOTES TO THE FINANCIAL STATEMENTS
(UNAUDITED)

This summary of accounting policies for Innovate Oncology, Inc. is presented to assist in
understanding the Company's financial statements.  The accounting policies conform to generally
accepted accounting principles in the United States of America and have been consistently applied
in the preparation of the financial statements.

Interim Reporting

The unaudited financial statements as of September 30, 2004 and for the three and nine
month period then ended, in the opinion of management, all adjustments (which include only normal
recurring adjustments) necessary to fairly state the financial position and results of operations for the
three and nine months.  Operating results for interim periods are not necessarily indicative of the
results which can be expected for full years.

Organization

Innovate Oncology, Inc., formerly known as Hampton Berkshire Insurance and Financial,
Inc., formally known as First Capital Resources.com, Inc. (the "Company") is a Nevada corporation,
having first been incorporated under the name Jackal Industries, Inc., pursuant to the laws of Utah
on April 16, 1986, and subsequently reorganized under the laws of Nevada on December 30, 1993.
During 1998, the Company ceased all business operations.  The Company's name was changed to
First Capital Resources.com, Inc., on April 13, 1999.  On February 7, 2003 the Company changed
its name to Hampton Berkshire Insurance and Financial, Inc. On September 28, 2004 the name was
changed to Innovate Oncology, Inc.   The Company has no products or services as of September 30,
2004.

Nature of Operations

The Company intends to acquire interests in various business opportunities, which in the
opinion of management will provide a profit to the Company.  In seeking a business opportunity to
merge with or acquire, management is reviewing various business plans. Management has not
limited their review of plans or exploration of acquisitions to any particular industry or service
sector. Management has not yet identified a business to complete such a transaction with and the
Company has not entered into any binding agreements for an acquisition or merger. There is no
assurance that the Company will be successful in finding any business opportunity to merge with or
acquire.



For purposes of the statement of cash flows, the Company considers all highly liquid debt

---



INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial Company)

NOTES TO  FINANCIAL STATEMENTS

(UNAUDITED)

Continued

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

instruments purchased with a maturity of three months or less to be cash equivalents to the extent
the funds are not being held for investment purposes.

Basis of Presentation

The Company's  financial statements have been prepared on a going concern basis, which
contemplates the realization of assets and satisfaction of liabilities in the normal course of business.
The  financial statements do not include any adjustment relating to recoverability and classification
of recorded amounts of assets and liabilities that might be necessary should the Company be unable
to continue as a going concern.  The Company has a substantial deficiency in assets.

The Company has entered into an agreement effective October 1, 2004, that subject to
certain conditions the Company will acquire all of the outstanding common stock of Innovate
Oncology, Inc.; a Delaware Corporation, in exchange for 15,900,000 common shares of the
Company.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period.  Actual results could differ from those estimates.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Deferred
income taxes are determined based on the estimated future tax effects of differences between the
financial reporting and tax reporting bases of assets and liabilities given the provisions of currently
enacted tax laws.  A valuation allowance is provided when it is more likely than not that all or some
portion of the deferred income tax asset will not be realized.

Net Loss Per Common Share

Basic net loss per common share is computed by dividing net loss by the weighted average
number of common shares outstanding during the year.  Diluted net loss per common share ("Diluted
EPS") reflects the potential dilution that could occur if stock options or other common stock

---

INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial Company)

NOTES TO  FINANCIAL STATEMENTS

(UNAUDITED)

Continued

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES
(Continued)

equivalents were exercised or converted into common stock.  The computation of Diluted EPS does
not assume exercise or conversion of securities that would have an antidilutive effect on net loss per
common share.

Comprehensive Income

There are no components of comprehensive income other than the net loss.

Derivative and Hedging Activities

Statement of Financial Accounting Standards (SFAS) No. 133, *Accounting for Derivative
Instruments and Hedging Activities*, as amended, requires that all derivative instruments be
recognized as either assets or liabilities at fair market value.  The adoption of this statement on
January 1, 2001 had no impact on the Company.

NOTE 2 - INCOME TAXES

Realization of the deferred tax asset is dependent on generating sufficient taxable income
prior to expiration of the loss carryforwards.  Management believes, based upon the short operating
period of the Company and the bankruptcy of the 92.85% Parent of the Company (Note 4), among
other things, the uncertainty of generating taxable income is such that it is more likely than not that
none of the deferred tax asset will be realized, and accordingly has established a valuation allowance
of $835,000 fully offsetting this asset.  It is reasonably possible the Company's estimate of
realizability of the deferred tax asset could materially change in the near term.Further, all or
substantially, all of the deferred tax asset may be lost due to the change in ownership on December
31, 2002.

---

NOTE 3 - COMMITMENTS

The Company currently maintains its corporate presence from the office of the Company's
legal counsel and pays no rent or expenses.



---



INNOVATE ONCOLOGY, INC.

(Formerly known as Hampton Berkshire Insurance & Financial Company)

NOTES TO  FINANCIAL STATEMENTS

(UNAUDITED)

Continued

NOTE 4 - COMMON STOCK TRANSACTIONS

On March 5, 2003, the Board of Directors changed the name of the Company to Hampton
Berkshire Insurance and Financial, Inc.  The Board  initiated a 1 for 10 reverse split of common stock
and increased the number of shares authorized to 150,000,000, consisting of 125,000,000 common
shares and 25,000,000 preferred shares to have such designations, preferences and rights as
determined by the board.

During the third quarter of 2004, shareholders voted to change the name to Innovate
Oncology, Inc. and effect a reverse split 3.8 to 1.  Fractional shares were rounded up to the next full
share and any shareholder that was reversed below one share will be reimbursed at par value for the
pre-reverse amount of shares.  All references to 2003 have been restated to reflect the stock split.

NOTE 5 - SUBSEQUENT EVENTS

On September 7, 2004, the Company entered into a agreement whereby the Company will
acquire 100% of the outstanding common stock of Innovate Oncology, Inc., a Delaware Corporation,
in exchange for 15,900,000 shares of the Company's common stock.  In connection with the
acquisition, 5,026,590 shares will be canceled.  After completion of the acquisition, the total
outstanding shares will be 17,353,242.

---

**ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS.**

RESULTS OF OPERATIONS

The following presentation of management's discussion and analysis of the Company's
financial condition and results of operation should be read in conjunction with the Company's
financial statements and notes contained herein.

Liquidity and Capital Resources.      The Company has entered into an agreement effective
October 1, 2004, that subject to certain conditions the Company will acquire all of the outstanding
common stock of Innovate Oncology, Inc.; a Delaware Corporation, in exchange for 15,900,000
come shares of the Company.  On September 28, 2004, the Company effected a reverse split of 3.8
to 1 of the Company's common stock.  Fractional shares were rounded up to the next full share and
any shareholder that was reversed below one share will be reimbursed at par value for the pre-reverse
amount of shares.

For the Three Months Ended.  The Company reported a net loss of $2,132 and $49,824 for
the quarters ended September 30, 2004, and September 30, 2003, respectively.

For the Nine months Ended.  The Company reported a net loss of $8,786 and $184,554 for
the quarters ended September 30, 2004 and September 30, 2003, respectively.  The Company
anticipates very little or no overhead from future operations other than interest, professional fees and
costs associated with being a public company, unless and until the agreement with Innovate
Oncology, Inc.; a Delaware Corporation is successful.



Plan of Operations.  ****The Company has entered into an agreement effective October 1,
2004, that subject to certain conditions the Company will acquire all of the outstanding common
stock of Innovate Oncology, Inc.; a Delaware Corporation, in exchange for 15,900,000 come shares
of the Company.****

**ITEM 3 - CONTROLS AND PROCEDURES.**

The Company's Chief Executive Officer and Chief Financial Officer have concluded,
based on an evaluation conducted within 90 days prior to the filing date of this Quarterly Report on
Form 10-QSB, that the Company's disclosure controls and procedures have functioned effectively
so as to provide those officers the information necessary whether:

(i) this Quarterly Report on Form 10-QSB contains any untrue statement of a material fact
or omits to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the
period covered by this Quarterly Report on Form 10-QSB, and

(ii) the financial statements, and other financial information included in this Quarterly
Report on Form 10-QSB, fairly present in all material respects the financial condition,
results of operations and cash flows of the Company as of, and for, the periods presented
in this Quarterly Report on Form 10-QSB.

There have been no significant changes in the Company's internal controls over financial

reporting or in other factors since the date of the Chief Executive Officer's and Chief Financial
Officer's evaluation that could significantly affect these internal controls, including any corrective
actions with regards to significant deficiencies and material weaknesses.     ****

---

**PART II - OTHER INFORMATION**

**ITEM 1.   LEGAL PROCEEDINGS**

None.

**ITEM 2.   CHANGES IN SECURITIES AND USE OF PROCEEDS**

On September 28, 2004, the Company effected a reverse split of 3.8 to 1 of the Company's
common stock.  Fractional shares were rounded up to the next full share and any shareholder that
was reversed below one share will be reimbursed at par value for the pre-reverse amount of shares.
Due to the reverse the amount of outstanding shares decreased from 24,624,198 to 6,479,832.

**ITEM 3.   DEFAULTS UPON SENIOR SECURITIES**

None.

**ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

****On September 28, 2004, security shareholders consented to a change in name to Innovate
Oncology, Inc. and to effect a 3.8 to 1 reverse split.

**ITEM 5.   OTHER INFORMATION**

The Company has entered into an agreement effective October 1, 2004, that subject to
certain conditions the Company will acquire all of the outstanding common stock of Innovate
Oncology, Inc.; a Delaware Corporation, in exchange for 15,900,000 come shares of the Company."

**ITEM 6.   EXHIBITS AND REPORTS ON FORM 8**

(a)   Exhibits.  The following exhibits are filed with this report.

31.  Written Statement of Chief Executive Officer and Chief Financial Officer with respect
to compliance with Section 13(a) or 15 (d) of the Securities Exchange Act of 1934 and Section 302
of the Sarbanes-Oxley Act of 2002.

32.  Written Statement of Chief Executive Officer and Chief Financial Officer with respect
to compliance with Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and pursuant to
18 U.S.C. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002.

(b)   Reports on Form 8-K.   The following reports have been filed on Form 8-K during the
last fiscal quarter:

1. September 23, 2004. Item 1.01 Entry into a Material Definitive Agreement. And Item
5.01 Changes in Control of Registrant.

SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned authorized officer.

By:/s/ Nigel RulewskiNigel Rulewski
CEO, President & Director
(Principal Executive Officer)

By: /s/ Alan Bowen

****Alan Bowen

CFO, Secretary, Treasurer & Director

(Principal Financial Officer)

---

**Exhibit 31.1**

**SECTION 302 CERTIFICATION**

I, Nigel Rulewski, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Innovate Oncology, Inc.;

2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.  Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;

4.  The registrant's other certifying officers and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in exchange act rules 13a-14 and 15d-14 for the registrant and
have:

a)  designed such disclosure controls and procedures to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b)  evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date
within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the effectiveness of the disclosure
controls and procedures based on our evaluation as of the Evaluation Date;

5.  The registrant's other certifying officers and I have disclosed, based on our most recent
evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons
performing the equivalent functions):

a)  all significant deficiencies in the design or operation of internal control which could adversely
affect the registrant's ability to record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in internal controls; and

b)  any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal controls.

6.  The  registrant's  other  certifying  officers  and I have indicated in this quarterly  report whether
or not there were significant changes in internal controls  or  in  other  factors  that  could significantly affect
internal controls subsequent to the date of my most recent evaluation, including any corrective  actions  with
regard  to significant deficiencies and material weaknesses.****

Date: November 5, 2004By:/s/ Nigel RulewskiNigel Rulewski

CEO, President & Director

(Principal Executive Officer)

---

**Exhibit 31.2**

**SECTION 302 CERTIFICATION**

1. I have reviewed this quarterly report on Form 10-QSB of Innovate Oncology, Inc.;

2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this quarterly report;

4.  The registrant's other certifying officers and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in exchange act rules 13a-14 and 15d-14 for the registrant and
have:

a)  designed such disclosure controls and procedures to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;

b)  evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date
within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and

c)   presented in this quarterly report our conclusions about the effectiveness of the disclosure
controls and procedures based on our evaluation as of the Evaluation Date;

5.  The registrant's other certifying officers and I have disclosed, based on our most recent
evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons
performing the equivalent functions):

a)  all significant deficiencies in the design or operation of internal control which could adversely
affect the registrant's ability to record, process, summarize and report financial data and have
identified for the registrant's auditors any material weaknesses in internal controls; and

b)  any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrant's internal controls.

6.  The  registrant's  other  certifying  officers  and I have indicated in this quarterly  report whether
or not there were significant changes in internal controls  or  in  other  factors  that  could significantly affect
internal controls subsequent to the date of my most recent evaluation, including any corrective  actions  with
regard  to significant deficiencies and material weaknesses.****

Date: November 5, 2004By: /s/ Alan Bowen

****Alan Bowen

CFO, Secretary, Treasurer & Director

(Principal Financial Officer)

---



Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Innovate Oncology, Inc., on Form 10-QSB for the period
ending Septempber 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the
*"Report"*), the undersigned, Nigel Rulewski, Chief Executive Officer and Principal Executive Officer of the
Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that:

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities
Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial
condition and result of operations of the Company.

Date: November 5, 2004By:/s/ Nigel RulewskiNigel Rulewski

CEO, President & Director

(Principal Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating,
acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version
of this written statement has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.

---



Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT BY

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities
Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial
condition and result of operations of the Company.

Date: November 5, 2004			By: /s/ Alan Bowen

****Alan Bowen

CFO, Secretary, Treasurer & Director

(Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating,
acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version
of this written statement has been provided to the Company and will be retained by the Company and
furnished to the Securities and Exchange Commission or its staff upon request.

---